These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29222257)

  • 1. Is molecular remission the goal of multiple myeloma therapy?
    Davies FE
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):205-211. PubMed ID: 29222257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple myeloma, immunotherapy and minimal residual disease.
    Kusenda J; Kovarikova A
    Neoplasma; 2016; 63(5):651-8. PubMed ID: 27468868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
    Yu Q; Shi JM; Tao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
    Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
    Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
    Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
    Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
    Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.
    Rawstron AC; Gregory WM; de Tute RM; Davies FE; Bell SE; Drayson MT; Cook G; Jackson GH; Morgan GJ; Child JA; Owen RG
    Blood; 2015 Mar; 125(12):1932-5. PubMed ID: 25645353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.
    Kunacheewa C; Lee HC; Patel K; Thomas S; Amini B; Srour S; Bashir Q; Nieto Y; Qazilbash MH; Weber DM; Feng L; Orlowski RZ; Lin P; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e221-e238. PubMed ID: 32037287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
    Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
    Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
    Landgren O; Lu SX; Hultcrantz M
    Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
    Rawstron AC; de Tute RM; Haughton J; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
    Guerrero C; Puig N; Cedena MT; Goicoechea I; Perez C; Garcés JJ; Botta C; Calasanz MJ; Gutierrez NC; Martin-Ramos ML; Oriol A; Rios R; Hernandez MT; Martinez-Martinez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Mosquera-Orgueira A; Gonzalez-Perez MS; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B
    Clin Cancer Res; 2022 Jun; 28(12):2598-2609. PubMed ID: 35063966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for operational cure in multiple myeloma.
    Mohty M; Avet-Loiseau H; Harousseau JL
    Blood; 2021 Oct; 138(16):1406-1411. PubMed ID: 34324647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost.
    Suzuki K
    Int J Hematol; 2020 Apr; 111(4):512-518. PubMed ID: 32125606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.